Apple, Masimo spar over Apple Watch import ban at US appeals court

Apple is appealing a U.S. trade tribunal's 2023 ruling that its Apple Watches infringed Masimo's pulse oximetry patents, which resulted in a U.S. import ban and the removal of the blood-oxygen feature. During arguments at the U.S. Court of Appeals for the Federal Circuit, Apple contended the ban was unjustified as Masimo's competing device was 'purely hypothetical' when the complaint was filed, while Masimo accused Apple of attempting to 'rewrite the law' and theft of its technology. The ongoing dispute will determine if Apple can restore a key health feature to its watches and carries broader implications for patent enforcement in the rapidly evolving consumer health technology sector.

Analysis

The legal battle between Apple (AAPL) and Masimo (MASI) has escalated to the U.S. Court of Appeals, where Apple is challenging a 2023 U.S. International Trade Commission (ITC) import ban on its smartwatches. The ban, which led Apple to disable the pulse oximetry feature on its Series 9 and Ultra 2 models in the U.S., stems from an ITC ruling that Apple infringed on Masimo's blood-oxygen measurement patents. Apple's core legal argument is that the ban was improper because Masimo's competing W1 watch was merely a 'hypothetical' concept when the complaint was filed in 2021, a year after Apple had already integrated the feature. Conversely, Masimo asserts that Apple stole its technology after partnership discussions and is attempting to 'rewrite the law' regarding the requirements for filing an ITC complaint. The stark contrast in ticker-specific sentiment, with AAPL at -0.7 and MASI at +0.7, underscores the perceived stakes: a significant product feature risk for Apple versus a substantial validation of intellectual property for Masimo. The court's decision will be pivotal, determining not only the future of a key Apple Watch health function but also setting a potential precedent for IP protection and competition within the lucrative consumer health technology sector.

Key Decisions for Investors

• Investors in Apple should monitor the appeal's outcome as a key catalyst, since a loss would solidify the removal of a significant health feature and could create a headwind for its wearables division's competitive positioning in the U.S.
• For investors in Masimo, a favorable ruling would further validate the strength and value of its patent portfolio, potentially creating leverage for a favorable settlement or licensing agreement with Apple.
• A key factor to watch is the court's interpretation of whether a company needs a finished product to file an ITC complaint, as the ruling could set a new precedent for IP litigation strategy in the tech industry.